UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 24, 2006
|
Pharmion Corporation |
|
|
|
(Exact name of registrant as specified in its charter) |
|
Delaware |
|
000-50447 |
|
84-1521333 |
|
|
|
|
|
|
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
2525 28th Street, Boulder, Colorado |
|
80301 |
|
|
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code 720-564-9100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
|
|
|
|
Item |
7.01 |
Regulation FD Disclosure |
|
|
|
|
|
|
|
On September 24, 2006, Pharmion Corporation issued a press release announcing top line results of the Phase 3 “SPARC” clinical trial evaluating satraplatin in patients with second-line hormone-refractory prostate cancer. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. |
|
|
|
|
|
|
|
In accordance with General Instruction B.2 of Form 8-K, the information incorporated by reference under this Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. |
|
|
|
|
|
Item |
9.01 |
Financial Statements and Exhibits. |
|
|
|
|
|
|
|
(d) Exhibits |
|
|
|
|
|
|
|
Exhibit |
|
Description |
|
|
|
|
|
|
|
99.1 |
|
Press Release, dated September 24, 2006. |
|
|
|
|
|
|
|
|
|
This exhibit is furnished pursuant to Item 7.01 and shall not be deemed to be “filed.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PHARMION CORPORATION |
|
|
|
|
|
|
|
|
|
|
|
|
Date: |
September 24, 2006 |
By: |
/s/ Erle T. Mast |
|
|
|
|
|
|
|
|
Name: |
Erle T. Mast |
|
|
|
Title: |
Chief Financial Officer |
|
|
|
|
|